A carregar...
The Argument Against a Biosimilar Switch Policy for Infliximab in Patients with Inflammatory Bowel Disease Living in Alberta
A nonmedical switch policy is currently being considered in Alberta, which would force patients on originator biologics to biosimilar alternatives with the hypothetical aim of reducing costs to the health care system. The evidence to support the safety of nonmedical switching in patients with inflam...
Na minha lista:
| Publicado no: | J Can Assoc Gastroenterol |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7465546/ https://ncbi.nlm.nih.gov/pubmed/32905124 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jcag/gwz044 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|